New ovarian cancer drug formulation put to the test
NCT ID NCT07371104
Summary
This study aims to see if a new drug called DWZ2501 behaves the same way in the body as an existing drug (DWC202510) for patients with advanced ovarian cancer linked to a BRCA gene change. It will involve about 40 women who are already taking or need to start the existing drug. The main goal is to compare how much of each drug gets into the bloodstream and how safe they are.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institutional Review Board of Seoul National University Hospital
RECRUITINGSeoul, Jongno-gu, 03080, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.